Argent Biopharma (ASX: RGT)

Last close As at 02/07/2024

AUD0.31

0.01 (3.33%)

Market capitalisation

Argent Biopharma is an Australia-headquartered specialist medical cannabis biopharma company, which has most of its operations based in Europe.

Latest Insights

View More

Sector

Healthcare

Equity Analyst

Nidhi Singh

Nidhi Singh

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Igor Bluvstein

    CFO

  • Roby Zomer

    Managing Director and Co-CEO

  • Yifat Steuer

    COO

Share Price Performance

Price Performance
% 1M 3M 12M
Actual -21.5 -28.7 -93.8
Relative -21.3 -28.3 -94.3
52 week high/low 6/0.295

Financials

Since beginning in earnest in August this year, 1,000 prescriptions for MGC’s phytocannabinoid products (CannEpil and MXP100) have been issued in Australia and the UK. Double the number of prescriptions were issued in October compared to September. Cash receipts for the quarter ending 30 September were A$413,000, with additional revenue of more than A$400,000 from recent sales expected to be received following the end of the quarter.

Y/E Jun Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2008A 0.1 (1.2) (1.4) (11.5) N/A N/A
2009A 0.1 (0.4) (0.7) (2.4) N/A N/A
2010E 0.5 (0.5) (0.6) (1.1) N/A N/A
2011E N/A N/A N/A N/A N/A N/A

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free